Keeley M. Cain Wettan net worth and biography

Keeley Cain Wettan Biography and Net Worth

Executive Vice President & General Counsel, Legal and Compliance of Gilead Sciences

Keeley Cain Wettan is Executive Vice President and General Counsel at Gilead. In this role, Keeley provides legal counsel to the Board of Directors and senior leadership, oversees all Legal and Compliance functions and manages the Corporate Responsibility team. Additionally, Keeley serves as Chair and Secretary of the Gilead Foundation. 

Since joining Gilead in 2011, Keeley has held numerous leadership positions that have shaped the company’s legal and compliance strategy. She previously served as Senior Vice President, Global Legal Business Partners, where she led teams responsible for providing legal counsel across Gilead’s business units worldwide. In earlier roles, Keeley also directed Litigation & Investigations, handling complex legal disputes and government inquiries, as well as Corporate Governance & Strategic Transactions, where she played a pivotal role in mergers, acquisitions and other strategic business initiatives. 

Her leadership continues to drive Gilead’s mission forward, ensuring that the company operates with the highest standards of ethics and responsibility while advancing groundbreaking therapies for patients around the world. 

Keeley has been guided by a strong commitment to integrity, collaboration and innovation throughout her career. Prior to joining Gilead, she practiced law at Simpson Thacher & Bartlett where she advised corporate clients on general litigation, government investigations and legal strategy, gaining valuable experience that laid the foundation for her future leadership roles. 

Keeley earned her Juris Doctor from the University of California, Berkeley School of Law.  

What is Keeley M. Cain Wettan's net worth?: The estimated net worth of Keeley M. Cain Wettan is at least $907.56 thousand as of November 6th, 2026. Ms. Cain Wettan owns 5,360 shares of Gilead Sciences stock worth more than $907,555 as of November 10th. This net worth approximation does not reflect any other investments that Ms. Cain Wettan may own. Learn More about Keeley M. Cain Wettan's net worth.
How do I contact Keeley M. Cain Wettan?: The corporate mailing address for Ms. Cain Wettan and other Gilead Sciences executives is 333 Lakeside DR, Foster City, CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Keeley M. Cain Wettan's contact information.
Has Keeley M. Cain Wettan been buying or selling shares of Gilead Sciences?: In the last ninety days, Keeley M. Cain Wettan has sold $557,809.89 of Gilead Sciences stock. Most recently, Keeley M. Cain Wettan sold 3,399 shares of the business's stock in a transaction on Friday, November 6th. The shares were sold at an average price of $164.11, for a transaction totalling $557,809.89. Following the completion of the sale, the executive vice president now directly owns 5,360 shares of the company's stock, valued at $879,629.60. Learn More on Keeley M. Cain Wettan's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Jeffrey Bluestone (Director), Keeley Cain Wettan (Executive Vice President & General Counsel, Legal and Compliance), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), Kelly Kramer (Director), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Daniel O'Day (Chairman and Chief Executive Officer), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Deborah Telman (Executive Vice President, Corporate Affairs and General Counsel), Robin Washington (CFO), Anthony Welters (Director), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 46 times. They sold a total of 760,746 shares worth more than $110,114,979.14. The most recent insider tranaction occured on November, 6th when EVP Keeley M. Cain Wettan sold 3,399 shares worth more than $557,809.89. Insiders at Gilead Sciences own 0.3% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 11/6/2026.

Keeley M. Cain Wettan Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/6/2026	Sell	3,399	$164.11	$557,809.89	5,360

Keeley M. Cain Wettan Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $169.32

$165.99

$170.11

50 Day Range

MA: $153.51

$143.72

$174.48

2 Week Range

Now: $169.32

$116.88

$176.58

Volume

4,470,244 shs

Average Volume

6,777,844 shs

Market Capitalization

$210.01 billion

P/E Ratio

N/A

Dividend Yield

1.96%

Beta

0.35